← ANALYST RATINGS · TIPRANKS
Ardelyx (ARDX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $13.43, the highest $18.00, the lowest $9.00. The average is +334.6% from the last price of $3.09.
Analyst ratings 9
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $3.50+16.7% | Hold | +13.3% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $3.50+16.7% | Hold | +13.3% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $3.50+16.7% | Hold | +13.3% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $3.50+16.7% | Hold | +13.3% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −2.9% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 | Hold | +13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 | Hold | +13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 | Hold | +13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Hold | +13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 | Hold | +13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 | Hold | +13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $9.00 | Buy | +191.3% | Reiterated | 18.08.26on TipRanks 06:05 | −2.8%next day +2.6% · 5 days −3.4% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $16.00 → $15.00−6.2% | Buy | +385.4% | Reiterated | 17.08.26on TipRanks 07:20 | +0.5%next day −2.8% · 5 days −6.7% | ↗ |
| Caroline Palomeque★★★★★★★★★★#12154 · hits 31% · avg −11.1% | Ladenburg Thalmann & Co. | $16.00 | Buy | +417.8% | Reiterated | 10.08.26on TipRanks Aug 17 07:20 | 0.0%next day −1.2% · 5 days +1.5% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $14.00 → $11.00−21.4% | Buy | +256.0% | Reiterated | 10.08.26on TipRanks 06:55 | 0.0%next day −1.2% · 5 days +1.5% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $19.00 → $15.00−21.1% | Buy | +385.4% | Reiterated | 07.08.26on TipRanks 09:40 | −18.5%next day 0.0% · 5 days +1.1% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $18.00 | Buy | +482.5% | Reiterated | 07.08.26on TipRanks 06:15 | −18.5%next day 0.0% · 5 days +1.1% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $13.00 → $10.00−23.1% | Buy | +223.6% | Reiterated | 06.08.26on TipRanks 21:50 | −18.5%next day 0.0% · 5 days +1.1% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $15.00 | Buy | +385.4% | Reiterated | 26.06.26on TipRanks 15:25 | −7.7%next day −7.4% · 5 days −6.8% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $17.00 | Buy | +450.2% | Reiterated | 20.02.26on TipRanks 06:35 | −15.7%next day +1.4% · 5 days +14.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Ardelyx
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.43 at a price of $3.42 (+292.6%); now: $13.43 at $3.09 (+334.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 6 | 10 | 8 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.01 (from $-0.06 to $0.03). Last quarter: $-0.07.
Sales
Next quarter’s sales estimate — $129M (from $120M to $135M). Last quarter: $121M.
Best top-analyst consensus in the sector · Healthcare
About Ardelyx
- CEO: Michael G. Raab
- Employees: 489
- 400 Fifth Avenue, Waltham, MA, 02451, US
- www.ardelyx.com
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 18 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗